4P-Phar­ma rais­es €15M; On­cotel­ic Ther­a­peu­tics sells rights to can­cer as­sets

Plus, news about Adap­tilens:

4P-Phar­ma se­cures €15M in sec­ond clos­ing: The fundraise, which was backed by pri­vate in­vestors, will be used to sup­port the French biotech as it us­es its “start­up stu­dio’s mod­el” to de­vel­op sin­gle prod­uct ve­hi­cles. The com­pa­ny’s lead can­di­date — a CX­CR4 an­tag­o­nist called 4P021 — is cur­rent­ly in Phase 2 de­vel­op­ment for acute res­pi­ra­to­ry dis­tress syn­drome.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER